Lite Strategy

Lite Strategy Net Debt/Equity

The Net Debt to Equity Ratio of Lite Strategy (LITS) as of Nov 20, 2026 is -3.57. In the previous year, Net Debt to Equity Ratio was -2.74 — a change of 30.38% (lower).

Net Debt/Equity

-3.57

YoY

30.38%

Last updated:

Net Debt to Equity Ratio of Lite Strategy is 2023 -3.57 . Net Debt to Equity Ratio of Lite Strategy was 2022 -2.74 . It decreases by 30.38% lower compared to the previous year.

The Lite Strategy Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2016
-1.10 USD
Jan 1, 2017
-1.06 USD
Jan 1, 2018
-2.03 USD
Jan 1, 2019
-1.56 USD
Jan 1, 2020
-2.37 USD
Jan 1, 2021
-2.93 USD
Jan 1, 2022
-2.74 USD
Jan 1, 2023
-3.57 USD
The Lite Strategy Net Debt/Equity history
YEARNet Debt/EquityYoY
-3.57+30.38%
-2.74-6.61%
-2.93+23.88%
-2.37+52.27%
-1.56-23.52%
-2.03+92.74%
-1.06-4.14%
-1.10+3.17%
-1.07-1.18%
-1.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lite Strategy Stock analysis

What does Lite Strategy do? MEI Pharma, Inc. develops cancer therapies, focusing on clinical drug candidates including Pracinostat, ME-344, and ME-401. Pracinostat, an HDAC inhibitor for hematologic diseases like AML and MDS, has undergone Phase I and II trials. ME-344 targets mitochondrial components in rapidly proliferating cells, while ME-401 inhibits PI3K delta for hematologic cancer treatment. The company generates revenue through clinical development and potential future drug sales, targeting oncology markets with its pipeline of cancer therapies. The firm's products are developed for specific cancer indications, with Pracinostat tested in advanced hematologic malignancies and solid tumors. ME-344 and ME-401 address unmet needs in mitochondrial and PI3K delta pathways, respectively. MEI Pharma's revenue model relies on clinical trial progress and future commercialization of these therapies, aiming to secure partnerships or direct sales in oncology. MEI Pharma's portfolio includes three clinical drug candidates, each targeting distinct cancer mechanisms. Pracinostat is advanced in trials for AML and MDS, while ME-344 and ME-401 are in development for broader cancer applications. The company monetizes through potential drug approvals and sales, with a focus on hematologic cancers and solid tumor markets. Lite Strategy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lite Strategy stock

Net Debt to Equity Ratio of Lite Strategy is -3.57 in 2023.

Net Debt to Equity Ratio of Lite Strategy changed from -2.74 to -3.57, representing a 30.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Lite Strategy since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Lite Strategy with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lite Strategy

All Key Metrics — Lite Strategy